• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to medicaments containing a pteridine of the formula <IMAGE> in which n is the number 0 or 1, R2 and R7 are each a pyrrolidino, piperidino or morpholino group which is optionally substituted by one or two methyl groups, R3 is a straight-chain or branched alkyl group in which one or two carbon atoms, excepting the carbon atom adjacent to the nitrogen atom, can be substituted by a hydroxyl group, R<4> is an alkyl or phenylalkyl group, in which one carbon atom, excepting the carbon atom adjacent to the nitrogen atom, can be substituted by a hydroxyl group, and R5 is a hydrogen atom or a methyl group, or the acid addition salts thereof and at least one chemotherapeutic from the natural product series, and to the use of the above pteridines for sensitisation of tumours during chemotherapy with the abovementioned chemotherapeutics, and to pteridines, process for the preparation thereof and medicaments containing these pteridines.
    公开号:SU1720491A3
    申请号:SU894742036
    申请日:1989-09-29
    公开日:1992-03-15
    发明作者:Хекель Армин；Лебзанфт Ерг；Бамбергер Уве；Раму Авнер
    申请人:Др.Карл Томэ Гмбх (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a method for producing new nitrogen-containing heterocyclic compounds having valuable pharmacological properties, in particular, to a method for producing pteridine derivatives of the general formula
    Yk
    Hun, „- С
    J4
    N N
     R,
    where R and Ra are substituted in position 2 or in positions 2 and 6 with the methyl morpholinogroup:
    lykie k on
    (I)
    whether g-
    RI and R2 - together with the nitrogen atom between them form N-ethyl-ethanolamino, N-ethyl-isopropanolamino, ethanol-isopropanol-amino, M- (2-hydroxy-2-methyl-n-propyl ethanolamine ;
    R is a hydrogen atom or methyl;
    n 0 or 1,
    which can be used as a means for sensitizing tumors characterized by primary or secondary resistance to chemotherapeutic agents.
    The purpose of the invention is the search for a method of obtaining new compounds in a number of pteridine derivatives, which have sensitized VI th o

    CJ
    effect on adriamycin-resistant sarcoma cells.
    The proposed method is that the compound of the general formula
    $ &
    where Ri, R2, R4 and p have the indicated meanings, one of the radicals Z or Zi means a nucleo-substitutable group, such as a halogen atom, for example a chlorine or bromine atom, and the other radical Z or Zi has the values indicated for R or R or means a nucleophilically substitutable group, such as a halogen atom, for example a chlorine or bromine atom, is reacted with a compound of the general formula
    H - X, (III)
    where X has the indicated values of the radical R or Yaz.
    The reaction is expediently carried out in an environment of a solvent, such as tetrahydrofuran. dioxane, benzene, toluene, dimethyl sulfoxide or dimethyl glycol ether, at 0-150 ° C, preferably between room temperature and the boiling point of the solvent used or in the melt. You can use an acid acceptor, such as sodium carbonate, triethylamine or pyridine.
    The starting compounds of the general formulas (H) and (III) are known or can be obtained by known methods.
    PRI me R 1.4- {M- (2-Oxy-2-methyl-n-propyl) -ethanolamine -2,7-bis-2,6-dimethyl-morpholino} -6-phenyl pteridine.
    a) 2,7-dichloro-4-H- (2-hydroxy-2-methyl-p-propyl) -ethanolamino-6-phenyl-pteridine.
    15.5 g (0.005 mol) of 2,4,7-trichloro-6-phenyl-pteridine is dissolved in 100 ml of acetone and then 13.3 g (0.1 mol) of M- (2-hydroxy- 2-methyl-n-propyl-ethanolamine. The mixture is stirred for 20 minutes at room temperature and 200 ml of water are added to the resulting suspension. The separated product is sucked off, washed with water and crystallized from methanol-water in accordance with 95: 5.
    Yield: t9.9 g (97% of theoretical), melting point 145-147 ° C.
    b) 4- {M- (2-hydroxy-2-methyl-n-propyl) -ethanolamine -2,7-bis- {2,6-dimethyl-morpholin-o) -6-pheny l-pteridine.
    2.0 tons (0.005 mol) of 2,7-dichloro-4- (AND- (2-ox-2-methyl-l-propyl) -ethanolamine-6-phenyl-pteridine is dissolved in 20 ml of diox - on and together with 3.5 g (0.08 mol) 2,6-dimethyl
    ten
    15 20
    25 30 35

    40
    45 50
    55
    morpholine is heated with reverse refrigeration for 30 minutes. Then the solution is poured into water, the precipitated precipitate is sucked off, washed with water and recrystallized from ethyl acetate.
    Yield 2.4 g (84% of theory), melting point 191-194 ° C.
    EXAMPLE 2. 4- {M-Ethyl-ethanolamino) -2.7-bis- (2,6-dimethyl-morpholino) 6-phenyl-pteridine is prepared from 4- (M-ethyl-ethanolamino ) -2,7-dichloro-6-phenyl-pteridine and 2,6-dimethyl-morpholine as in example 1.
    Yield 81% of theory, melting point 128-138 ° C (ethanol).
    EXAMPLE 3. 4- (Ethanol-isopropanolamino) -2,7-bis-2,6-dimethyl-morpholino) -6-phenyl-pteridine is prepared from 4- (ethanol-isopropanolamino) - 2,7-dichloro-6-phenyl-pteridine and 2,6-dimethyl-morpholine as in example 1.
    Yield 60% of theoretical, melting point 192-193 ° C (methanol - water in the ratio 4: 1).
    EXAMPLE 4. (2-Hydroxy-2-methyl-n-propyl) -ethanolamine -2,7-bis- (2-methyl-morpholino) -6-phenyl-pteridine is prepared from 4 - {M- (2-hydroxy-2-methyl-p-propyl-ethanolamine -2,7-dichloro-6-phenyl-pteridine and 2-methyl-morpholine as in Example 1.
    The yield is 74% of the theoretical, melting point 143-147 ° C (ethyl acetate - petroleum ether).
    TI p and m e r 5. 4- (Ethanol-isopropanolamino) -2,7-bis- (2-methyl-morpholino) -6-benzyl-pteridine is obtained from 4- (ethanol-isopropanolamino) -2,7-dichloro-b-benzylpteridine and 2-methyl-morpholine as in Example 1.
    Yield 55% of theory, melting point 100-105 ° C.
    EXAMPLE 6. 4- (Ethanol-isopropanolamino) -2,7-bis- (2-methyl morpholino) -6- (o-tolyl) -pteridine is prepared from 4- (ethanol iso- propanolamine) -2,7-dichloro-6- (o-tolyl) - pteridine and 2-methyl-morpholine as in example 1.
    Yield 85% of theory, melting point. 105-110 ° C (reprecipitation from 0.1N hydrochloric acid).
    PRI me R 7.4-M- {2-hydroxy-2-methyl-n-propyl) -ethanolamine -2,7-bis- (cis-2,6-dimethyl-morpholino) -6-phenyl- pteridine is obtained from 4-Shch2-hydroxy-2-methyl-n-propyl) -ethanolamine-, 7-dichloro-6-phenyl-pteridine and cis-2,6-dimethyl-morpholine as in Example 1.
    Yield 60% of theory, melting point 206-209 ° C (isopropanol).
    The use of compounds of examples 1-7 as a means for sensitization of tumors with primary or secondary resistance to chemotherapeutic agents.
    7-Benzylamino-4- (M-methyl-21-hydroxyethylamino} -2-piperazino-pteridine was used as a comparison.
    The effects of these compounds were investigated on the example of resistant cells as follows.
    Adriamycin-resistant sarcomal S180 cells released from mice were cultured for 6 days in the presence of different concentrations of the test substances. An indicator of the cytotoxic or cytostatic effect of the concentrations of the test substances is a decrease in cell growth or cell death. At the end of the experiment, the number of viable cells per culture was determined indirectly by establishing the ability of viable cells to restore MTT dye (3- (4,5-dimethyl-thiazol-2-yl) -2,5-diphenyltetrazol bromide) to the corresponding formazan . The concentration of the test substance was determined, capable of reducing the amount of control (hereinafter referred to as KUY). The test substances were studied both in the absence of adriamycin and in the presence of an amount of adriamycin (ADR) that did not inhibit polyplication under cultivation conditions. Therefore, for each test substance, KVso values were obtained (the first was in the presence of ADRs, i.e. CUzo ADR, the second, in the absence of ADRs, i.e. CUzo. The difference in the ten logarithms of both values CUd A log CUADADR caused by the presence of adriamycin.In addition, cell resistance to ADR is eliminated.
    Exponentially growing, adriamycin resistant or sensitive to adriamycin S180 cells were placed in flat-bottomed microtiter plates with 96 wells (2000 cells / well), each of which contained 100 µl of the culture medium (RPMI-1640 containing 10% fetal blood serum of cattle ). The plates were incubated in a thermostat at 37 ° C and a relative humidity of 100% in the presence of 5% carbon dioxide. After 24 hours, 50 µl of nutrient medium containing different concentrations of the test substance and 50 µl of nutrient medium without adriamycin or with adriamycin were added to the recess. Within 6 days of cultivation, 50 μl of a solution of tetrazolium salt, 5 mg of 3- (4,5-dimethyl-thiazol-2-yl) -2,5-diphenyltetrazolm bromide was added to each well with each pipette and diluted with 5% phosphate buffer solution. prior to use with RPMI-1640 medium in a 1: 5 volume ratio. After 4 hours of incubation, the culture medium was carefully aspirated and the resulting
    0 formazan solubilized inside the cells with the addition of 150 μl dimethylsulfoxide / well. The plates were briefly shaken and the optical density at 570 nm was measured using a photometer.
    5 (Dinech MR-600). Formation of the formation by reduction of the tetrazolium salt is proportional to the number of viable cells. The average values obtained as a result of a threefold analysis
    0 was used to calculate the Cuso values (dilution ratio 1: 2).
    The results of the experiment are shown in the table.
    These tables confirm that
    lteridines of general formula (I) differ
    5 rkovyrazhennym sensitizing effect on adriamycin-resistant sarcoma cells and therefore, in combination with alkaloids from VINCA, epipodofillotok- sinami or antibiotics such as dau0 norubitsin, doxorubicin, bleomycin, mithramycin or mitomycin year are for the treatment of neoplastic diseases, in order to eliminate their stability to appropriate chemotherapy and in this way
    5 to ensure the weakening of tumors resistant to these substances. The pteridines of formula (I), together with a chemotherapeutic agent, prevent the treatment of tumor subpopulations that can resist the therapy and thus cause a relapse.
    The pteridine derivatives of formula (I) belong to the category of low-toxic substances.
    权利要求:
    Claims (1)
    [1]
    5 claims
    The method of obtaining pteridine derivatives of the general formula
    RI-, g N
    Rt
    iJjLwtiu-Q
    where R and Ra are substituted in position 2 or in positions 2 and 6 with methyl morpholinoprop;
    RI and R 2 together with the nitrogen atom between them form N-ethyl-ethanolamino, N-ethyl-isopropanolamino, ethanol-isopropanolamino, M- (2-hydroxy-2-methyl-n-propyl} -ethanolamino;
    R4 is hydrogen or methyl;
    n - 6 or 1.
    about tl and h and y y and with the fact that the compound of the general formula
    where Ri, RZ. R4 and l have the indicated meanings; ten
    one of the radicals Z or Zi is a nucleophile interchangeable group, and the other radical Z or Zi has the meanings indicated for R or Ra, or also means a nucleophilic substitutable group, is reacted with a compound of the general formula
    Hh
    where X has the indicated values of R or Ra, followed by isolation of the desired product.
    There is no activity even about a concentration of 100 µg / ml.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1720491A3|1992-03-15|Method of pteridin derivatives synthesis
    JP4276376B2|2009-06-10|Heterocyclic compounds and antitumor agents containing the same as active ingredients
    JP5448455B2|2014-03-19|Novel 3&#39;-, 7-substituted indirubins and their applications
    CN101787025B|2012-06-20|Substituted-evodiamine anti-tumor and antifungal compounds and preparation method thereof
    US4556654A|1985-12-03|Antimicrobial substituted anthra[1,9-cd]pyrazol-6|-ones
    US2965643A|1960-12-20|Derivatives of pyrazolo
    CN110330474B|2021-06-18|Preparation of apigenin-dithiocarbamate derivative and anti-tumor application
    US6057326A|2000-05-02|Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
    JP2012517465A|2012-08-02|Azaindole derivatives as inhibitors of protein kinases ABL and SRC
    US4904659A|1990-02-27|Substituted quinoline derivatives and pharmaceutical compositions thereof
    US9388209B2|2016-07-12|2′, 3′-dideoxy-5-fluorouridine derivatives, a process for the manufacture thereof and application thereof
    EP0103381B1|1987-09-23|Substituted anthra|pyrazol-6|-ones
    EP0046572B1|1984-10-31|6-quinazolinesulfonyl derivatives and process for preparation thereof
    US10766862B2|2020-09-08|Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
    JPH0733743A|1995-02-03|2-aryl-4-quinolinol derivative
    PL179170B1|2000-07-31|Novel compounds, derivatives of genistein
    US4814445A|1989-03-21|Process for preparing mitomycin analogs
    US5434155A|1995-07-18|Quinoline derivative fumarates
    CN112047950A|2020-12-08|Imidazopyrazine derivative and synthesis method and application thereof
    US4055642A|1977-10-25|Imidazolyl-2-quinazoline derivatives
    DK168708B1|1994-05-24|Process for Preparation of N7-Amidino Substituted Mitomycin C Derivatives
    Kundu et al.1982|N-Alkylated derivatives of 5-fluorouracil
    US3948908A|1976-04-06|Pyridopyridazine derivatives
    Abraham et al.1969|Single crystal studies of chemotherapeutic agents. I. Structure of 1-|-3-|-. DELTA. 2-1, 2, 3-triazolinium chloride
    US3954768A|1976-05-04|2-|ethyl cycloaminocarbodithioates
    同族专利:
    公开号 | 公开日
    ES2056174T3|1994-10-01|
    AT106728T|1994-06-15|
    FI92699C|1994-12-27|
    DK480489A|1990-04-02|
    DD299062A5|1992-03-26|
    PT91836B|1995-07-18|
    DE3833393A1|1990-04-05|
    IL91814A|1994-02-27|
    NO893879D0|1989-09-29|
    IL91814D0|1990-06-10|
    AU4174989A|1990-04-05|
    EP0362645A3|1992-03-25|
    AU620645B2|1992-02-20|
    ZA897414B|1991-06-26|
    NO175979B|1994-10-03|
    DK480489D0|1989-09-29|
    DE58907824D1|1994-07-14|
    FI894615A|1990-04-02|
    PT91836A|1990-04-30|
    HU205761B|1992-06-29|
    UA8028A1|1995-12-26|
    HUT52504A|1990-07-28|
    NO893879L|1990-04-02|
    KR910006289A|1991-04-29|
    NO175979C|1995-01-11|
    NZ230833A|1991-05-28|
    EP0362645B1|1994-06-08|
    JPH02256676A|1990-10-17|
    EP0362645A2|1990-04-11|
    FI894615A0|1989-09-29|
    MX9203034A|1992-07-01|
    FI92699B|1994-09-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    RU2447074C2|2005-05-12|2012-04-10|Тиботек Фармасьютикалз Лтд.|Pteridines effective as hcv inhibitors and methods for producing pteridines|US3574206A|1965-04-15|1971-04-06|Boehringer Sohn Ingelheim|2,7-dimorpholino-4-amino-6-phenyl-pteridines|
    NL129630C|1966-10-14|
    DE1617336C2|1966-11-25|1982-07-01|C.H. Boehringer Sohn, 6507 Ingelheim|Medicines for angina pectoris|
    DE1795515A1|1967-08-18|1972-03-30|Thomae Gmbh Dr K|Process for the production of new pteridines|
    DE1795516A1|1967-12-15|1972-01-27|Thomae Gmbh Dr K|4-AEthanolisopropanolamino-2- -7-morpholino-6-phenyl-pteridine|
    DE1921308A1|1969-04-25|1971-01-07|Boehringer Sohn Ingelheim|Pharmaceutical prepns. containing one or more of cpds. of general formula :- ArOCH2 - CHOH - CH2 - NHR Ar= opt. mono-or polysubstd. iso-, hom|
    US4767761A|1987-11-04|1988-08-30|Dana-Farber Cancer Institute, Inc.|Ornithine derivatives and their use as methotrexate-resistant cell inhibitors|DE69920757T2|1998-12-28|2005-12-15|4 AZA Bioscience N.V.|IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES|
    US7276506B2|1998-12-28|2007-10-02|4 Aza Bioscience Nv|Immunosuppressive effects of pteridine derivatives|
    DE10202468A1|2002-01-23|2004-09-30|Faustus Forschungs Cie. Translational Cancer Research Gmbh|Pteridine derivatives, process for their preparation and their use|
    PL1663244T3|2003-09-12|2008-01-31|4 Aza Ip Nv|Pteridine derivatives for the treatment of tnf-alpha-related diseases.|
    ES2293354T3|2003-10-17|2008-03-16|4 Aza Ip Nv|PTERIDINE DERIVATIVES REPLACED BY HETEROCICLES AND ITS USE IN THERAPY.|
    US10144736B2|2006-07-20|2018-12-04|Gilead Sciences, Inc.|Substituted pteridines useful for the treatment and prevention of viral infections|
    SG11201606876RA|2015-03-04|2016-10-28|Gilead Sciences Inc|Toll like receptor modulator compounds|
    KR20160003575A|2015-11-09|2016-01-11|정민시|Power transmitting apparatus for generator|
    US10370342B2|2016-09-02|2019-08-06|Gilead Sciences, Inc.|Toll like receptor modulator compounds|
    EP3507288B1|2016-09-02|2020-08-26|Gilead Sciences, Inc.|4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE3833393A|DE3833393A1|1988-10-01|1988-10-01|USE OF PTERIDINES TO PREVENT PRIMARY AND SECONDARY RESISTANCE IN CHEMOTHERAPY AND MEDICINES CONTAINING THESE COMPOUNDS|
    [返回顶部]